Showing 121-130 of 155 results for "".
- New AAAHC COVID-19 Guidelines Call for Postponing Elective or Non-Essential Visits and Surgerieshttps://practicaldermatology.com/news/new-aaahc-covid-19-guidelines-call-for-postponing-elective-or-non-essential-visits-and-surgeries/2460323/The Accreditation Association for Ambulatory Health Care (AAAHC) is calling for the postponement of elective or non-essential visits or surgeries in their newly released guidelines. For patients that require an office visit, increased pre-screening measures with specific questions related to rec…
- FDA Greenlights Pfizer’s Eucrisa for Children As Young As Three Months With ADhttps://practicaldermatology.com/news/fda-greenlights-pfizers-eucrisa-for-children-as-young-as-three-months-with-ad/2460321/The U.S. Food and Drug Administration (FDA) gave its nod to Pfizer’s Eucrisa ointment, 2%, for children as young as age 3 months with mild-to-moderate atopic dermatitis (AD). Eucrisa was previously approved for use in adults and children 2 years of age and older. It is the first and only steroid-f…
- Arcutis Biotherapeutics Plans to Initiate Phase 3 Program for ARQ-151 for Plaque Psoriasishttps://practicaldermatology.com/news/arcutis-biotherapeutics-plans-to-initiate-phase-3-program-for-arq-151-for-plaque-psoriasis/2460196/Arcutis Biotherapeutics, Inc. plans to initiate its Phase 3 program of ARQ-151 as a potential topical treatment for plaque psoriasis following its End-of-Phase 2 meeting with the FDA. The Company anticipates initiating a Phase 3 clinical trial in the first half of 2020. Frank Watanabe, Arcutis’ Pr…
- Dermira Shares Positive Data From Phase 2b Study of Lebrikizumab for Atopic Dermatitis at Fall Clinical Dermatology Conferencehttps://practicaldermatology.com/news/dermira-shares-positive-data-from-phase-2b-study-of-lebrikizumab-for-atopic-dermatitis-at-fall-clinical-dermatology-conference/2460190/Primary results from Dermira, Inc.'s Phase 2b dose-ranging study of lebrikizumab were presented during the 39th Annual Fall Clinical Dermatology Conference in Las Vegas, NV. Lebrikizumab is currently being evaluated in a Phase 3 program in adult and adolescent patients with moderate-to-severe atopi…
- International Council Of Dermatologists Introduces New Method Of Determining Psoriasis Severityhttps://practicaldermatology.com/news/international-council-of-dermatologists-introduces-new-method-of-determining-psoriasis-severity/2460155/A new method to classify psoriasis severity can determine the appropriate course of treatment, according to a consensus paper by the International Psoriasis Council (IPC). The paper is published in the Journal of the American Academy of Dermatology. “There's a lot of unnecessary suffering among p…
- Kamedis: Clinical Study Validates Traditional Chinese Botanical for Eczemahttps://practicaldermatology.com/news/kamedis-clinical-study-validates-traditional-chinese-botanical-for-eczema/2460020/Traditional Chinese botanicals in homeopathic over-the-counter Kamedis Calm Eczema Therapy Cream play a pivotal role in the product’s ability to reduce eczema rashes, according to results of a new study announced by the company. Results show that commercially available Kamedis cream was 44% mor…
- SkinBioTherapeutics Names New Executive Directorhttps://practicaldermatology.com/news/skinbiotherapeutics-names-new-executive-director/2460012/Stuart Ashman is the new executive director of SkinBioTherapeutics. Mr. Ashman will succeed Professor Cath O’Neill as CEO after a period of transition. Ms. O’Neill will continue to drive the science and the ongoing commercial discussions she has initiated. He brings more than two decades of comme…
- Derm Students Improve Wikipedia Entries on Skin Disease, Boost Viewshttps://practicaldermatology.com/news/derm-students-improve-wikipedia-entries-on-skin-disease-boost-views-1/2459992/A group of medical students recruited to improve Wikipedia articles on skin-related diseases and saw millions more views of those stories following their editing, a new study shows. "We tried to make the articles more readable, while adding more relevant information," says Olivia Hutton, BS, a med…
- Dr. Sandra Marchese Johnson, Yoseph Dalia Win Practical Dermatology®'s Best Paper of 2018 Awardhttps://practicaldermatology.com/news/dr-sandra-marchese-johnson-yoseph-dalia-win-practical-dermatologys-best-paper-of-2018-award/2459950/Fort Smith, Arkansas-based dermatologist Sandra Marchese Johnson MD, FAAD and Yoseph Dalia, BS took home Practical Dermatology®’s Best Paper of 2018 award for a Resident Resource Center submission that detailed the first reported case of facial rash following dupilumab therapy for atopic dermatitis…
- Encore Dermatology Announces Phase 2 Safety Data for Impoyzhttps://practicaldermatology.com/news/encore-dermatology-announces-phase-2-safety-data-for-impoyz/2457496/A Phase 2, open-label study published in SKIN The Journal of Cutaneous Medicine, found that subjects treated with Impoyz (clobetasol propionate) Cream, 0.025% showed significantly lower mean post-treatment clobetasol propionate plasma concentrations versus the subjects treated with Temovate (clobet…